Who are Hyaluronate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Synvisc-One, viscosupplementation 1+1+1, knee injection, Volbella or Juvederm Ultra XC filler, HA 0.3%, High hyal Plus inj..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hyaluronic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Hyaluronate — Competitive Intelligence Brief

Hyaluronate (HYALURONIC ACID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: hyaluronic acid. Area: Metabolic.

marketed hyaluronic acid Metabolic Live · refreshed every 30 min

Target snapshot

Hyaluronate (HYALURONIC ACID).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Hyaluronate TARGET	HYALURONIC ACID		marketed	hyaluronic acid
Synvisc-One	Synvisc-One	Nature Cell Co. Ltd.	marketed	Viscosupplement; hyaluronic acid derivative	Synovial fluid; joint cartilage surfaces
viscosupplementation 1+1+1	viscosupplementation 1+1+1	University of Sao Paulo General Hospital	marketed	Hyaluronic acid derivative; viscosupplement	Hyaluronic acid receptor (CD44); joint synovial fluid
knee injection	knee injection	OSF Healthcare System	phase 3	Corticosteroid or Hyaluronic acid
Volbella or Juvederm Ultra XC filler	Volbella or Juvederm Ultra XC filler	DeNova Research	phase 3	Hyaluronic acid filler
HA 0.3%	HA 0.3%	Huons Co., Ltd.	phase 3	Hyaluronic acid derivative	Hyaluronic acid receptors (CD44, RHAMM)
High hyal Plus inj.	High hyal Plus inj.	Huons Co., Ltd.	phase 3	Hyaluronic acid derivative	Hyaluronic acid receptors (CD44, RHAMM)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (hyaluronic acid class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hyaluronate — Competitive Intelligence Brief. https://druglandscape.com/ci/hyaluronic-acid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab